Loading
NASDAQHealthcareBiotechnology
Latest quote
$168.35
−$1.73 · -1.02%
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Previous close
$168.35
−$1.73 · -1.02%
Regular session · ET · Market data may be delayed.
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Day range
Current $168.35
52-week range
Current $168.35
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
66
Undervalued
Sentiment
64
Bullish
Risk
27
Moderate Risk
Momentum
59
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Day range
Current $168.35
52-week range
Current $168.35
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 638.5M USD | 385.69M USD | 270.6M USD | 50.04M USD | — |
| Cost of goods sold | 47.48M USD | 33.3M USD | 26.07M USD | 5.2M USD | — |
| Gross profit | 591.02M USD | 352.39M USD | 244.54M USD | 44.84M USD | — |
| Research and development | 183.28M USD | 187.08M USD | 97.94M USD | 57.95M USD | 58.06M USD |
| Selling, general, and administrative | 570.6M USD | 411.36M USD | 323.12M USD | 159.25M USD | 66.65M USD |
| Operating expenses | 760.25M USD | 632.95M USD | 476.36M USD | 224.64M USD | 124.71M USD |
| Interest income | 9.37M USD | — | — | — | — |
| Interest expense | 6.56M USD | 6.57M USD | 6.45M USD | 7.34M USD | 5.7M USD |
| Depreciation and amortization | 9.06M USD | 7.96M USD | 6.83M USD | 4.4M USD | 76K USD |
| Operating income | −169.24M USD | −280.56M USD | −231.83M USD | −179.8M USD | −124.71M USD |
| Net income | −183.17M USD | −287.22M USD | −239.24M USD | −187.13M USD | −130.4M USD |
Company facts updated Oct 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI276.28M0.01%2.3T USD0.03%$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB199.8M0.11%185.3B USD0.03%$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK114.68M0.25%44.7B USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF99.72M0.10%95.4B USD0.05%$235+0.80%
First Trust NYSE Arca Biotechnology Index FundFBT65.19M2.25%2.89B USD0.55%$265.4+2.00%
iShares Biotechnology ETFIBB58.05M0.55%10.82B USD0.44%$206.49+3.00%
iShares Russell Mid-Cap Growth ETFIWP41.35M0.21%20.1B USD0.23%$143.1+1.56%
Schwab U.S. Small-Cap ETFSCHA40.17M0.18%21.82B USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFFirst Trust NYSE Arca Biotechnology Index FundFBTiShares Biotechnology ETFIBBiShares Russell Mid-Cap Growth ETFIWPSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
